Skip to main content

ImmunoGen stock rockets after ovarian cancer treatment shows ‘meaningful’ survival benefit

ImmunoGen's stock soared toward a record a record gain Wednesday, after a trial of the biotech's ovarian cancer treatment produced positive survival data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.